Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Sold by Avalon Trust Co

Avalon Trust Co decreased its position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 36.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 2,650 shares of the company’s stock after selling 1,500 shares during the quarter. Avalon Trust Co’s holdings in Nurix Therapeutics were worth $50,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the company. US Bancorp DE grew its holdings in Nurix Therapeutics by 144.7% in the 4th quarter. US Bancorp DE now owns 1,424 shares of the company’s stock valued at $27,000 after buying an additional 842 shares during the period. Amalgamated Bank grew its holdings in Nurix Therapeutics by 30.6% in the 3rd quarter. Amalgamated Bank now owns 2,182 shares of the company’s stock valued at $49,000 after buying an additional 511 shares during the period. Quarry LP grew its holdings in Nurix Therapeutics by 3,746.2% in the 3rd quarter. Quarry LP now owns 2,500 shares of the company’s stock valued at $56,000 after buying an additional 2,435 shares during the period. Quest Partners LLC grew its holdings in Nurix Therapeutics by 21.3% in the 3rd quarter. Quest Partners LLC now owns 7,458 shares of the company’s stock valued at $168,000 after buying an additional 1,312 shares during the period. Finally, Bellevue Group AG purchased a new stake in Nurix Therapeutics in the 3rd quarter valued at about $180,000.

Nurix Therapeutics Stock Up 3.0 %

Shares of NRIX opened at $13.59 on Friday. The business’s 50 day moving average is $17.54 and its two-hundred day moving average is $21.17. Nurix Therapeutics, Inc. has a 52-week low of $11.90 and a 52-week high of $29.56. The firm has a market cap of $1.03 billion, a price-to-earnings ratio of -4.70 and a beta of 2.18.

Nurix Therapeutics (NASDAQ:NRIX) last announced its earnings results on Tuesday, January 28th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.08). Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. On average, equities analysts expect that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have commented on NRIX shares. Royal Bank of Canada lifted their price target on Nurix Therapeutics from $26.00 to $27.00 and gave the company an “outperform” rating in a report on Wednesday, January 29th. Morgan Stanley boosted their target price on Nurix Therapeutics from $16.00 to $17.00 and gave the stock an “equal weight” rating in a report on Monday, February 3rd. Stephens reiterated an “overweight” rating and set a $31.00 target price on shares of Nurix Therapeutics in a report on Tuesday, January 21st. Needham & Company LLC decreased their target price on Nurix Therapeutics from $29.00 to $28.00 and set a “buy” rating for the company in a report on Wednesday, January 29th. Finally, Stifel Nicolaus boosted their target price on Nurix Therapeutics from $34.00 to $36.00 and gave the stock a “buy” rating in a report on Wednesday, January 29th. One research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $31.81.

Insider Buying and Selling at Nurix Therapeutics

In other Nurix Therapeutics news, CFO Houte Hans Van sold 5,825 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $14.49, for a total value of $84,404.25. Following the transaction, the chief financial officer now directly owns 33,724 shares of the company’s stock, valued at $488,660.76. This represents a 14.73 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Gwenn Hansen sold 3,690 shares of the company’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total value of $73,246.50. Following the sale, the insider now directly owns 55,937 shares in the company, valued at approximately $1,110,349.45. This represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 12,326 shares of company stock valued at $213,449 in the last three months. Corporate insiders own 7.20% of the company’s stock.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.